Nab-Paclitaxel

Drug Class:

• Antimicrotubule agent (taxane), albumin-bound formulation of paclitaxel.

Key Formulation Point:

• Uses albumin nanoparticles instead of Cremophor EL (polyoxyethylated castor oil) as a solvent.
• This eliminates the need for routine corticosteroid/antihistamine premedication, reduces severe hypersensitivity risk, and allows shorter infusion time.

Mechanism of Action:

• Binds to β-tubulin subunit of microtubules → promotes microtubule assembly and inhibits depolymerization.
• Arrests cell cycle in the G₂/M phase → apoptosis.
• Albumin facilitates tumor uptake via gp60-mediated endothelial transcytosis and SPARC (secreted protein acidic and rich in cysteine) binding in tumor stroma.

Oncology Indications:

• Metastatic breast cancer after failure of combination chemo or within 6 months of adjuvant therapy.
• NSCLC (with carboplatin) in patients not candidates for surgery/radiation.
• Metastatic pancreatic adenocarcinoma (with gemcitabine).
• PD-L1+ triple-negative breast cancer (with atezolizumab).

Adult Dosing Examples:

• Breast cancer: 260 mg/m² IV over 30 min q3 weeks.
• NSCLC: 100 mg/m² IV on days 1, 8, 15 of a 21-day cycle (with carboplatin day 1).
• Pancreatic cancer: 125 mg/m² IV on days 1, 8, 15 of a 28-day cycle (with gemcitabine).
• TNBC + atezolizumab: 100 mg/m² IV on days 1, 8, 15 q28 days.

Pharmacokinetics:

• Metabolism: hepatic via CYP2C8 (major) and CYP3A4.
• Elimination: fecal; minimal renal excretion.
• t½: ~27 hours.

Toxicities to Monitor:

• Myelosuppression — especially neutropenia (dose-limiting).
• Peripheral neuropathy — may occur earlier than with conventional paclitaxel.
• Alopecia.
• Fatigue.
• GI: nausea, vomiting, diarrhea.
• Rare: interstitial pneumonitis, severe hypersensitivity.

Administration & Monitoring Points for Pharmacists:

• Infuse over 30 minutes; no in-line filter required.
• Premedication not routinely required, but may be given if patient had prior mild reaction.
• Monitor CBC prior to each dose, LFTs, and neuropathy symptoms.
• Avoid strong CYP2C8/CYP3A4 inhibitors or inducers.
• Do not substitute mg-for-mg with conventional paclitaxel — they are not bioequivalent.

Clinical Pearls:

• Shorter infusion time (30 min) improves patient convenience.
• Reduced hypersensitivity risk is particularly helpful in patients unable to tolerate standard paclitaxel premedications (e.g., diabetics sensitive to steroids).
• Neuropathy tends to be earlier onset but more reversible if managed promptly with dose modifications.